Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERRELL DOW's SELDANE U.S. RETAIL SALES ANNUALIZING AT OVER $120 MIL

Executive Summary

MERRELL DOW's SELDANE U.S. RETAIL SALES ANNUALIZING AT OVER $120 MIL. (at pharmacy acquisition cost), based on January-July retail sales figures reported in Pharmaceutical Data Services' (PDS) most recent AlphaGram. Entering its third year of marketing, Seldane "continues its tremendous growth while dominating the single entity prescription antihistamine U.S. retail market," PDS commented. The pharmaceutical auditing service estimates that January to July sales for the Rx nonsedating antihistamine Seldane (terfenadine) were $71 mil., a 44% gain over the $49 mil. in sales generated by the product during the comparable 1986 period. However, PDS noted that Seldane's "dominant position could be threatened upon approval of Janssen's Hismanal (astemizole), which currently has an NDA pending." An NDA for Schering-Plough's loratidine is also pending approval at FDA. Other nonsedating antihistamine products in the R&D pipeline include Burroughs Wellcome's acrivastine (Phase III clinical studies), Pfizer's certirizine (Phase III studies), and SmithKline's temelastine (Phase II studies). Based on PDS data, Seldane was the top new Rx retail product in 1985 following its launch in May of that year. At the end of 1985, PDS audit data showed retail sales of the nonsedating antihistamine annualizing at about $50 mil. Even if Seldane U.S. sales were to level off during the next five months, they would still be roughly 33% over 1986 sales figures. Last year, sales of Seldane in the U.S. topped $90 mil., according to Merrell Dow.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel